-
Novel Gene Therapy for Cystic Fibrosis (Post)
Novel Gene Therapies for Cystic Fibrosis Cystic Fibrosis Cystic fibrosis (CF) is an autosomal recessive, life-limiting disease resulting from gene mutations that encode the cystic fibr
Cation and Inorganic Ion Assays(Page) A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics(Post)A New Dawn in Lupus Treatment: The Promise of Topical RNA Therapeutics Systemic Lupus Erythematosus (SLE) is a debilitating autoimmune disease that has long puzzled researchers and clinicians. Howeve
ELISA Troubleshooting: Total Protein Normalization in Lysates(Post)QUICK ANSWER A researcher ran a panel of EMT-marker ELISA kits (E-cadherin, claudin-1, N-cadherin, vimentin, ZEB1, TWIST1) on breast cell-line lysates and found E-cadherin reading "pos
In Vivo depletion atlas(Page) Physiological and Pathological functions of IL-36(Post)By Charlotte O'Donnell PhD Similar to IL-33, IL-36R ligands are involved in maintaining intestinal homeostasis. Analogous to IL-33, d is locali
von Willebrand Factor and Cancer(Post)What is von Willebrand Factor? Von Willebrand Factor (VWF) is a crucial glycoprotein that plays a fundamental role in blood clotting and hemostasis. Produced by endot
Bermekimab: Unveiling the Role of Anti-CD47 in Hidradenitis Suppurativa and Atopic Dermatitis(Post)What You Need to Know About BermekimabWhat is Bermekimab?Bermekimab is a monoclonal antibody targeting the CD47 receptor, developed to modulate the immune system and improve conditions l
The Role of ACE2 in SARS-CoV-2(Post)Structure, Function, and Detection Assays for COVID-2019 Background The global spread of the novel cor
IL-10 signalling and regulation(Post)Explore the complexities of Interleukin-10 (IL-10) signaling and regulation, a crucial aspect in immune response modulation and its dual roles in cancer development and therapy. Key Takeaways:
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars(Post)Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
Chronic myelogenous leukaemia (CML) – Review(Post)Chronic myelogenous leukaemia (CML) is a myeloproliferative haematopoietic malignancy, characterised by a karyotypic abnormality present in more than 95% of cases known as the Philadelph
Gram-Negative Bacteria: Examples, Infections & Resistance(Post)What is Gram-Negative bacteria? Gram-negative bacteria are a diverse group of microorganisms characterized by their unique cell wall structure. They stain pink or red when subjecte
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
PD-1/PD-L1 Checkpoint Signalling: Pathway, Function and Assays(Post)PD-1 does not switch a T cell off; it moves the threshold. Engagement of PD-1 by PD-L1 recruits a single phosphatase into the immunological synapse, and that one recruitment event is enough to collap
Bersanlimab: Revolutionizing Cancer Research with Anti-CD47 Therapeutics(Post)What You Need to Know About BersanlimabWhat is Bersanlimab?Bersanlimab is a cutting-edge anti-CD47 monoclonal antibody designed to disrupt cancer cells' evasion of immune detection.What
Avizakimab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About AvizakimabWhat is Avizakimab?Avizakimab is a monoclonal antibody designed to target the CD47 protein, a key checkpoint in immune regulation, particularly in cancer ther
After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b
Complement: The Brake Matters More Than the Trigger(Post)Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase
Icatolimab: Revolutionizing the Fight Against Cancer via CD47 Targeting(Post)Quick Facts About IcatolimabWhat is Icatolimab?Icatolimab is a monoclonal antibody designed to target CD47, a protein that cancer cells use to evade immune detection.How does Icatolimab